5-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(dimethylamino)ethyl]oxolane-2-carboxamide
C19H26N8O2 — CID 163256890
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(dimethylamino)ethyl]oxolane-2-carboxamide
5-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(dimethylamino)ethyl]oxolane-2-carboxamide (PubChem CID 163256890) has the molecular formula C19H26N8O2 and a molecular weight of 398.47 g/mol. Its IUPAC name is 5-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(dimethylamino)ethyl]oxolane-2-carboxamide.
Molecular Properties
| Compound Name | 5-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(dimethylamino)ethyl]oxolane-2-carboxamide |
|---|---|
| PubChem CID | 163256890 |
| Molecular Formula | C19H26N8O2 |
| Molecular Weight | 398.47 g/mol |
| Exact Mass | 398.22 |
| IUPAC Name | 5-[4-amino-5-(1-methylpyrazol-3-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(dimethylamino)ethyl]oxolane-2-carboxamide |
| SMILES | CN(C)CCNC(=O)C1CCC(n2cc(-c3ccn(C)n3)c3c(N)ncnc32)O1 |
| InChI | InChI=1S/C19H26N8O2/c1-25(2)9-7-21-19(28)14-4-5-15(29-14)27-10-12(13-6-8-26(3)24-13)16-17(20)22-11-23-18(16)27/h6,8,10-11,14-15H,4-5,7,9H2,1-3H3,(H,21,28)(H2,20,22,23) |
| InChIKey | LSNMRHZVEAKIRF-UHFFFAOYSA-N |
| XLogP | 0.77 |
| TPSA | 116.12 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 398.47 |
| LogP ≤ 5 | 0.77 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 163256890 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.